The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial
Open accessAbstract
BACKGROUND: Antidepressants are used both for treating acute episodes and for prophylaxis to prevent future episodes of depression, also called maintenance treatment. This article describes the protocol for a randomised controlled trial (ANTLER: ANTidepressants to prevent reLapse in dEpRession) to investigate the clinical effectiveness and cost-effectiveness in UK primary care of continuing on long-term maintenance antidepressants compared with a placebo in preventing relapse of depression in those who have taken antidepressants for more than 9 months and who are currently well enough to consider stopping maintenance treatment. METHODS/DESIGN: The ANTLER trial is an individually randomised, double-blind, placebo-controlled trial in which participants are randomised to remain on active medication or to take an identical placebo after a tapering period of 2 months. Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication. The participants will be followed up at 6, 12, 26, 39 and 52 weeks. The primary outcome will be the time in weeks to the beginning of the first episode of depression after randomisation. This will be measured using a retrospective version of the Clinical Interview Schedule-Revised administered at 12, 26, 39 and 52 weeks. Secondary outcomes will include depressive and anxiety symptoms, adverse effects, withdrawal symptoms, emotional processing tasks, quality of life and the resources and costs used. We will also perform a cost-effectiveness analysis based on results of the trial. DISCUSSION: The ANTLER trial findings will inform primary care prescribing practice by providing a valid and generalisable estimate of the clinical effectiveness and cost-effectiveness of long-term maintenance treatment with antidepressants in UK primary care. TRIAL REGISTRATION: Controlled Trials ISRCTN Registry, ISRCTN15969819. Registered on 21 September 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two of the secondary outcomes the time until stopping the medication and the patient's mood - were prespecified in the statistical analysis plan before the database lock but after the protocol had been published.”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One review author (TK) was involved in two ongoing trials (Duffy 2019; ISRCTN12417565).None of the other review authors was involved in any of the included trials.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Duffy 2019
The cited source says what the claim attributes to it.
In the citing paper
“We determined that the enrollment of 479 patients would provide the trial with 90% power to detect a hazard ratio of 1.92 for the primary outcome in the discontinuation group on the basis of an estimated relapse frequency of 20% in the maintenance group and 35% in the discontinuation group at a two-sided alpha level of 0.05, assuming 20% attrition.”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Lewis, G., Pelosi, A. J., Araya, R., & Dunn, G. (1992) · Psychological Medicine · doi:10.1017/s0033291700030415 · Cited by 1,487
Self-citationKarolinska Directed Emotional Faces
Lundqvist, D., Flykt, A., & Öhman, A. (2015) · PsycTESTS Dataset · doi:10.1037/t27732-000 · Cited by 1,313
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Full publication of results initially presented in abstracts.
Scherer, R. W., Langenberg, P., & von Elm, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000005.pub3 · Cited by 997
Cited by
Maintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192
Self-citationVan Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Self-citationStimpfl, J. N., Walkup, J. T., Robb, A. S., Alford, A. E., Stahl, S. M., McCracken, J. T., Stancil, S. L., Ramsey, L. B., Emslie, G. J., & Strawn, J. R. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0099 · Cited by 32
“In the largest study of antidepressant discontinuation in adults, patients treated with fl uoxetine 20 mg daily were discontinued by taking fl uoxetine 20 mg every other day for a month and then discontinuing (Duffy et al., 2019).”
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 27
Self-citationMcGowan, N. M., Rucker, J., Yehuda, R., Agrawal, M., Modlin, N. L., Simmons, H., Tofil-Kaluza, A., Das, S., & Goodwin, G. M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251362390 · Cited by 25
“The Modified Discontinuation Emergent Signs and Symptoms Scale (mDESS) was used to assess the tolerability of antidepressant/antipsychotic medication withdrawal during run-in (Duffy et al., 2019).”
Metadata
- Authors
- Duffy, L., Bacon, F., Clarke, C. S., Donkor, Y., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., King, M., Lanham, P., Lewis, G., Mangin, D., Marston, L., Moore, M., Nazareth, I., Wiles, N., & Lewis, G.
- Affiliations
- University College London (GB)
- The Royal Free Hospital (GB)
- University of York (GB)
- University of Southampton (GB)
- University of Bristol (GB)
- University of Otago (NZ)
- Corresponding author
- Duffy, Larisa
- ORCID
- Venue
- Trials
- Published
- 2019-06-03
- Volume
- 20
- Issue
- 1
- Pages
- 319-319
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC6547591
- OpenAlex
- W2948678705
- Cited by
- 22
- References
- 31
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 5 · 2021: 4 · 2020: 2 · 2019: 4
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Trials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, cc-by)
- Bristol Research (University of Bristol) (publishedVersion, cc-by)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Health Technology Assessment Programme (13/115/48)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depression relapse prevention, antidepressant tapering, citalopram, sertraline, fluoxetine, mirtazapine, primary care, cost-effectiveness, withdrawal symptoms, quality of life
- MeSH terms
- Mirtazapine, Adult, Aged, Antidepressive Agents, Cost-Benefit Analysis, Depression, Double-Blind Method, Fluoxetine, Humans, Middle Aged, Primary Health Care, Recurrence, Retrospective Studies, Citalopram, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care, Sample Size, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-019-3390-8
- The paper
- Duffy, L., Bacon, F., Clarke, C. S., Donkor, Y., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., King, M., Lanham, P., Lewis, G., Mangin, D., Marston, L., Moore, M., Nazareth, I., Wiles, N., & Lewis, G. (2019). A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials. https://doi.org/10.1186/s13063-019-3390-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.